IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives
This study has been completed.
Sponsor:
Boehringer Ingelheim
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00539487
First received: September 25, 2007
Last updated: November 7, 2013
Last verified: November 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This observational non-interventional study will assess (under conditions of clinical practice in daily routine) the antihypertensive efficacy of telmisartan treatment with or without active promotion of lifestyle changes in hypertensive patients at high cardiovascular risk
| Condition |
|---|
| Hypertension Obesity |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | TOP -Study Telmisartan - Therapy of Hypertension and Life-style Changes in Cardiovascular Risk Patients |
Resource links provided by NLM:
Further study details as provided by Boehringer Ingelheim:
Primary Outcome Measures:
- Blood pressure reduction [ Time Frame: 4 month ]
Secondary Outcome Measures:
- Change in metabolic parameters Safety [ Time Frame: n.a. ]
| Enrollment: | 5827 |
| Study Start Date: | January 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Study Design:
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
hypertensive patients
Criteria
Inclusion Criteria:
patients with essential hypertension aged >/= 18 years with one of the following risk factors: history of coronary artery disease or stroke/TIA or peripheral artery disease or diabetes mellitus.
Exclusion Criteria:
according to SPC
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00539487
Show 2389 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00539487
Show 2389 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
More Information
| Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT00539487 History of Changes |
| Other Study ID Numbers: |
502.523 n.a. |
| Study First Received: | September 25, 2007 |
| Last Updated: | November 7, 2013 |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases Telmisartan |
Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on July 21, 2017